Chondrial Therapeutics Inc., a clinical-stage biotechnology company co-founded by IU School of Medicine Professor of Pediatrics R. Mark Payne, MD in 2011, announced earlier this month that its flagship compound is entering Phase 1 clinical trial to evaluate the safety and tolerability of single ascending doses. The drug is intended to treat Friedreich’s ataxia, a rare but debilitating genetic disorder for which there are no approved treatments.
“Due to a genetic abnormality, patients with FA don’t produce enough of an important protein called frataxin,” said Payne. “CTI-1602 is the only frataxin replacement therapy in clinical development, and this trial will bring us closer to improved treatment for the thousands of people who are affected.”
Estimated to impact about 1 in 50,000, Friedreich’s ataxia is the most common heritable neurodegenerative condition. Typically diagnosed between the ages of 10 and 15, Friedrich’s ataxia affects multiple systems in the body, including the brain and the heart. As a result, children and young adults with Friedreich’s ataxia progressively lose the ability to walk and speak, and their risk for heart failure and other conditions are increased.
Payne is also the chief scientific officer of Chondrial Therapeutics, which announced a definitive merger agreement with biopharmaceutical company Zafgen on December 18. According to a joint press release, “the proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.”
About IU School of Medicine
IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report. The school offers high-quality medical education, access to leading medical research and rich campus life in nine Indiana cities, including rural and urban locations consistently recognized for livability.
About Chondrial Therapeutics
Chondrial Therapeutics is a clinical-stage biotechnology company focused on the treatment of complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Chondrial Therapeutics also plans to use its protein replacement therapy platform to design other fusion proteins to target additional orphan diseases characterized by deficiencies in intracellular bioactive compounds. Learn more at www.chondrialtherapeutics.com.
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company that has leveraged its proprietary MetAP2 biology platform to pioneer the study of MetAP2 inhibitors in both common and rare metabolic disorders. Learn more at www.zafgen.com.